ANGELHOLM, Sweden, Sept. 14 /PRNewswire/ -- HemoCue today introduces a
 new system for point-of-care testing of blood glucose with lab quality
 accuracy, at the Annual Meeting of the European Association for the Study
 of Diabetes (EASD) in Copenhagen. The new HemoCue Glucose 201 RT has a
 wider measuring range than current HemoCue glucose systems and uses
 microcuvettes that are room temperature stable. This system has just
 received FDA 510(k) clearance for the US, and allows blood glucose to be
 measured with high precision and accuracy anywhere, anytime.
     The HemoCue Glucose 201 RT is a further advance in blood glucose
 systems by HemoCue, the manufacturer of the only dedicated point-of-care
 glucose systems that are FDA cleared in the US for diagnosis, screening and
 monitoring of diabetes mellitus. The new system has a significantly wider
 measuring range compared to the current generation. An additional
 improvement is that the microcuvettes can be stored at room temperature.
     Dr. Nichols, Associate Professor of Pathology at Tufts University
 School of Medicine and an active member of the American Association for
 Clinical Chemistry says: "Blood glucose devices have become smaller, faster
 and require less blood. However, there is still a great need for
 point-of-care glucose systems with higher precision and accuracy.
 Calibration bias coupled with lot-to-lot variations may in some instances
 lead to errors in measurement and subsequent diagnosis or treatment."
     In a study that was presented at the AACC meeting in Chicago in July by
 Dr. Ulf Hannestad, University of Linkoping, Sweden, the HemoCue Glucose 201
 RT was compared to a mass spectrometry reference method for measuring
 glucose. The study confirmed the system's excellent precision and accuracy,
 features that enable HemoCue Glucose 201 RT to be used not only for
 accurate monitoring of diabetes mellitus but also for screening and
 diagnosis at the point-of-care.
     "Advances in instrument technology and microcuvette chemistry were
 combined to bring high accuracy and precision over a wider range and room
 temperature handling convenience for the user in the HemoCue Glucose 201
 RT," says Stellan Lindberg, Director of R&D at HemoCue. "It is now a lot
 easier for the user to accurately monitor glucose levels in any
 environment. We expect that these improvements will bring many benefits to
 our customers."
     The HemoCue Glucose 201 RT is displayed for the first time at the EASD
 congress in Copenhagen, September 14-17. The system will be launched in the
 Nordic countries in September, with further introductions planned directly
 thereafter in Europe, the US, and the rest of the world.
     About HemoCue AB
     HemoCue AB is a leader in the development, manufacturing, and marketing
 of advanced medical testing systems that bring lab quality results to the
 point-of-care. Its major products include hemoglobin, glucose, and
 urine-albumin testing systems. The fundamental concept behind the HemoCue
 products is the ability to perform common blood and urine tests at the
 point-of-care with the same accuracy and precision offered by a central
 clinical lab.
     HemoCue is a Swedish based company acting globally and is owned by EQT,
 a leading private equity group in Northern Europe.
     For additional information about HemoCue, or its products and services,
 visit http://www.hemocue.com
 
 

SOURCE HemoCue AB